Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...

Bullous Pemphigoid Market Outlook 2025-2035: The 7 major Bullous Pemphigoid market reached a value of USD 287.1 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,618.1 ...

Autoimmune bullous diseases are often associated with significant morbidity and some can even cause mortality, if left untreated. Multiple therapies are now available to treat these blistering ...

KANSAS CITY, Mo. – Patrick Mahomes and the Kansas City Chiefs are in the midst of a dynasty. The back-to-back Super Bowl champion Chiefs defeated the Buffalo Bills 32-29 in a back-and-forth ...

1 Department of Oral Mucosa, Qingdao Stomatological Hospital Affiliated to Qingdao University, Qingdao, China 2 Department of Oral Medicine, Peking University School and Hospital of Stomatology, ...